Table 1.

Characteristis of the patients, treatments and KPC-producing Klebsiella pneumoniae isolates

	Diagnosis and antimicrobial treatment	Date	Isolate (Specimen)	Synergy tests/blaKPC-2	Sequence type	PFGE (XbaI)
Patient A	SLE, Enteric Salmonella sepsis; CIP	20/02
	Escherichia coli Tracheobronchitis; PTZ	27/02
	Pseudomonas aeruginosa VAP with secondary bacteraemia; IMP	10 al 23/03
	P. aeruginosa persistent tracheal	26/03	A1 (Urine)	+/nd	nd	nd
	Samonella bacteraemia and Septic shock; IMP plus CIP	30/03 31/03	A2 (Urine)	+/+	ST258	A
		06/04	A3 (Catheter)	+/nd	nd	nd
Patient B	Chest trauma, respiratory failure, Diabetic; PTZ	15/03
	P. aeruginosa VAP with secondary bacteraemia; IMP	20 al 30/03
	P. aeruginosa persistent tracheal infection	1 al 09/04
	Mechanical ventilation reinstalled	07/04	B1 (TA) B2 (Catheter)	+/+ +/+	ST258 nd	A A
	KPC-KP VAP, Septic shock; DOX plus RIF plus MEM	09/04	B3 (TA) B4 (Urine) B5 (Rectal) B6 (TA)	+/nd +/nd +/nd +/+	nd nd nd ST258	nd nd nd A
	TIG plus RIF plus MEM Respiratory failure, P. aeruginosa bacteraemia	14/04 28/04

CIP, ciprofloxacin; PFGE, pulsed-field gel electrophoresis; PTZ, piperacillin-tazobactam; IPM, imipenem; DOX, doxycycline; RIF, rifampin; MEM, meropenem; TYG, tigecycline; A₁, >10⁵ CFU/mL K. pneumoniae and P. aeruginosa; A₂, >10⁵ CFU/mL of K. pneumoniae; A₃, 10 CFU of K. pneumoniae in the tip of central line catheter; B₂, 100 CFU of K. pneumoniae; B₄, >10⁵ CFU mL⁻¹ of K. pneumoniae; +, difference of ≥5 mm in zones between MEM and MEM plus boronic acid and <5 mm in zone between MEM and MEM plus cloxacillin and MEM plus dipicolinic acid; nd, not determined; SLE, systemic lupus erythematosus; VAP, ventilator-associated pneumonia; TA, tracheal aspirate.